Tarsus Pharmaceuticals, Inc. expanded its Board of Directors from seven to eight members and appointed David E.I. Pyott as a Class III director, effective February 18, 2026. Mr. Pyott was also appointed Chairperson of the Commercial Committee and member of the Nominating and Compensation Committees, with an initial equity grant valued at $540,000.
Key takeaways
Board expanded from 7 to 8 directors on February 18, 2026
David E.I. Pyott appointed as Class III director with term expiring at 2026 annual meeting
Mr. Pyott appointed Chairperson of Commercial Committee and member of Nominating and Compensation Committees
Mr. Pyott determined independent under Nasdaq and SEC standards
Initial compensation grant of $540,000 (50% options, 50% RSUs) per non-employee director policy
Entered into indemnification agreement with Mr. Pyott